# Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

> **NCT04820933** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 26 (actual)

## Conditions studied

- HIV I Infection
- Cardiovascular Risk Factor
- Lipid Metabolism Disorders

## Interventions

- **DRUG:** Doravirine 100 Mg

## Key facts

- **NCT ID:** NCT04820933
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2025-10-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04820933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04820933, "Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04820933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*